We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Axonics (AXNX) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Axonics Modulation Technologies (AXNX - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Axonics Modulation Technologies is a member of our Medical group, which includes 1187 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Axonics Modulation Technologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AXNX's full-year earnings has moved 15.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AXNX has returned about 15% since the start of the calendar year. In comparison, Medical companies have returned an average of -17.2%. This means that Axonics Modulation Technologies is outperforming the sector as a whole this year.
Another stock in the Medical sector, GlycoMimetics (GLYC - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 18.1%.
In GlycoMimetics' case, the consensus EPS estimate for the current year increased 6.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Axonics Modulation Technologies belongs to the Medical Info Systems industry, which includes 49 individual stocks and currently sits at #88 in the Zacks Industry Rank. On average, stocks in this group have lost 45.3% this year, meaning that AXNX is performing better in terms of year-to-date returns.
On the other hand, GlycoMimetics belongs to the Medical - Drugs industry. This 218-stock industry is currently ranked #84. The industry has moved -29.6% year to date.
Investors with an interest in Medical stocks should continue to track Axonics Modulation Technologies and GlycoMimetics. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Axonics (AXNX) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Axonics Modulation Technologies (AXNX - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Axonics Modulation Technologies is a member of our Medical group, which includes 1187 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Axonics Modulation Technologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AXNX's full-year earnings has moved 15.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AXNX has returned about 15% since the start of the calendar year. In comparison, Medical companies have returned an average of -17.2%. This means that Axonics Modulation Technologies is outperforming the sector as a whole this year.
Another stock in the Medical sector, GlycoMimetics (GLYC - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 18.1%.
In GlycoMimetics' case, the consensus EPS estimate for the current year increased 6.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Axonics Modulation Technologies belongs to the Medical Info Systems industry, which includes 49 individual stocks and currently sits at #88 in the Zacks Industry Rank. On average, stocks in this group have lost 45.3% this year, meaning that AXNX is performing better in terms of year-to-date returns.
On the other hand, GlycoMimetics belongs to the Medical - Drugs industry. This 218-stock industry is currently ranked #84. The industry has moved -29.6% year to date.
Investors with an interest in Medical stocks should continue to track Axonics Modulation Technologies and GlycoMimetics. These stocks will be looking to continue their solid performance.